MGMT promoter methylation, tumor

Alphabetical Test listing

MGMT promoter methylation, tumor-Pathology add-on

MGMT promoter methylation, tumor
Pathology add-on

Prognostication of newly diagnosed glioblastomas Identifying newly diagnosed glioblastomas that may respond to alkylating chemotherapy (ie, temozolomide) Guiding therapy decision making for newly diagnosed glioblastomas in elderly patients (>60 years)


At least 40% tumor is required for this assay. In general, a 6 mm x 3 mm area of tissue cut at 5 micron thickness is the minimum amount of tissue needed; this could be collected over multiple slides.


Submit processed tissue block


Formalin-fixed, paraffin-embedded (FFPE) tissue block


One (1) slide stained with hematoxylin and eosin and five (5) unstained, non-baked 5-micron thick sections of the tumor


Ambient (preferred)



Mayo Clinic Laboratories (MGMT): R
Weekly; varies
7 - 10 days

Methylation-specific Polymerase Chain Reaction (PCR) analysis


An interpretive report will be provided.

81287 - slide review